The following article from the UK MS Trust (a charity) website provides further details about the optic neurosis trial with Aimspro.
Aimspro trial results presented
Doctors in Oxford who conducted a small trial of Aimspro as a treatment for optic neuritis presented their results at a meeting of the Association of British Neurologists (ABN) in Belfast on 1 April.
This is the first randomised double blind placebo controlled trial of the drug. The small trial recruited twelve people who had some continuing loss of vision following earlier optic neuritis. Participants were on active treatment for two weeks.
Researchers found that the two main outcome measures of the trial were negative. These measures were visual evoked potential amplitude or latency, and amplitude of the BOLD (blood oxygen level dependent) response in fMRI experiments.
A third exploratory outcome measure, the effect on visual field size, showed apparent improvement in patients on Aimspro not seen in the placebo group. However this effect was not significantly different to placebo. The drug was well tolerated and no serious side effects were observed during the short course of the trial.
These results do not justify the very positive message put out by the manufacturer, Daval International, which appeared on the national ITV news on 21 March, and subsequently in some of the national papers.
At the manufacturer's request, another study of the drug has been halted. This trial, at St George's Hospital in Tooting, was investigating Aimspro as a treatment for secondary progressive MS.
There is currently no peer reviewed published evidence of efficacy or safety for this treatment.